Abstract
As with any disease, there are three general options for treatment of AML: supportive care only, standard therapy, and investigational therapy. Although, as discussed below, there are instances where the first option is preferable, the natural history of AML typically mitigates against it [1]. Since by definition there is much more information available about standard than about investigational therapy, most patients prefer the former, provided outcome with it is satisfactory. Hence, this review will begin by describing standard therapy, with emphasis on the factors that predict success following its use. Subsequent discussion will focus on investigational options of potential use for patients in whom results with standard therapy are poor.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Freireich EJ, Gehan EA, Sulma D, et al. (1961) The effect of chemotherapy on acute leukemia in the human. J Chron Dis 14: 593–608
Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620–625
de Lima M, Strom S, Keating M, et al. (1997) Implications of potential cure in acute myelogenous leukemia: Development of subsequent cancer and return to work. Blood 90:4719–4724
Buchner T, Urbanitz D, Hiddemann W, et al. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3:1583–1589
Buchner T, Hiddemann W, Berdel B (2001) Requestioning the role of prolonged maintenance chemotherapy in AML: A randomized trial by the German AML Cooperative Group. Blood 98:462a
Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE (2001) Attempts to improve treatment outcomes in AML in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 98:1302–1311
Charlson ME, Pompei P, Ales KL, et al. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chr Dis 40:373–383
Sorror MI, Maris MB, Storer B, et al. (2004) Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplantation comorbidities. Blood 104:961–968
Grimwade D, Walker H, Oliver F, et al. (1998) The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukemia Working Parties. Blood 92:2322–2333
Grimwade D, Walker H, Harrison G, et al. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia: Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 98:1312–1320
Slovak ML, Kopecky KJ, Cassileth PA, et al. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075–4083
Downing JR (2003) The core-binding factor leukemias: Lessons learned from murine models. Curr Opin Genet Dev 13:48–54
Bloomfield CD, Lawrence D, Byrd JC, et al. (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173–4179
Goldstone AH, Burnett AK, Avivi I, et al. (2002) Secondary AML has a worse outcome than de novo AML even taking into account cytogenetics and age. AML 10,11,12 MRC trials. Blood 100:88a (abstr)
Nguyen S, Leblanc T, Fenaux P, et al. (2002) A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): A survey of 161 cases from the French AML Intergroup. Blood 99:3517–3523
Schlenk RF, Benner A, Krauter J, et al. (2004) Individual patient data-based meta-analysis of patients aged 16–60 years with core binding factor acute myeloid leukemia: A survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 15:3741–3750
Marcucci G, Mrózek K, Ruppero AS, et al. (2005) Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B Study. J Clin Oncol 23:5705–5717
Care RS, Valk PJ, Goodeve AC, et al. (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 121:775–777
Carioli R, Beghini A, Grillo G, et al. (2006) Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study. Blood 107:3463–3468
Schnittger S, Kohl TM, Haferlach T, et al. (2006) KIT-D816 mutations in AML1-ETO positive AML are associated with impaired event-free and overall survival. Blood 107:1791–1799
Paschka P, Marcucci G, Ruppert A, et al. (2006) Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A cancer and leukemia group B (CALGB) study. Proc Am Soc Clin Oncol 24:1 (abstr)
Yokota S, Kiyoi H, Nakao M, et al. (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: A study on a large series of patients and cell lines. Leukemia 10:1605–1609
Kottaridis PD, Gale RE, Frew ME, et al. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752–1759
Fröhling S, Schlenk RF, Breitruck J, et al. (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100:4372–4380
Thiede C, Steudel C, Mohr B, et al. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326–4335
Whitman SP, Archer KJ, Feng L, et al. (2001) Absence of the wildtype allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group B study. Cancer Res 61:7233–7239
Yamamoto Y, Kiyoi H, Nakano Y, et al. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97:2434–2439
Fröhling S, Scholl C, Gilliland DG, Levine RL (2005) Genetics of myeloid malignancies — Pathogenetic and clinical implications. J Clin Oncol 23:6285–6295
Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T (2005) Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: A meta-analysis. Leukemia 19:1345–1349
Mead A, Linch D, Hills R, et al. (2005) Favorable prognosis associated with FLT3 tyrosine kinase domain mutations in AML in contrast to the adverse outcome associated with internal tandem duplications. Blood 106:334 (abstr)
Falini B, Mecucci C, Tiacci E, et al. (2005) Gimema Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254–266
Döhner K, Schlenk RF, Habdank M, et al. (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics — Interaction with other gene mutations. Blood 106:3740–3746
Verhaak RGW, Goudswaard CS, van Putten W, et al. (2005) Mutations in nucleophosmin NPM1 in acute myeloid leukemia (AML): Association with other genetic abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106:3747–3754
Schnittger S, Schoch C, Kern W, et al. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106: 3733–3739
Suzuki T, Kiyoi H, Ozeki K, et al. (2005) Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 106:2854–2861
Bowen DT, Frew ME, Hills R, et al. (2005) RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients < 60 yrs. Blood 106:2113–2119
Preudhomme C, Sagot C, Boissel N, et al. (2002) Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood 100:2717–2723
Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Meijer J, et al. (2003) Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediaterisk AML. Hematol J 4:31–40
Fröhling S, Schlenk RF, Stolze I, et al. (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624–633
Caligiuri MA, Schichman SA, Strout MP, et al. (1994) Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. Cancer Res 54:370–373
Caligiuri MA, Strout MP, Lawrence D, et al. (1998) Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58:55–59
Döhner K, Tobis K, Ulrich R, et al. (2002) PPrognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: A study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 20:3254–3261
Steudel C, Wermke, Schaich M, et al. (2003) Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer 37:237–251
Baldus CD, Tanner SM, Ruppert AS, et al. (2003) BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B Study. Blood 102:1613–1618
Bienz M, Ludwig M, Mueller BU, et al. (2005) Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 11:1416–1424
Bullinger L, Valk PJM (2005) Gene expression profiling in acute myeloid leukemia. J Clin Oncol 23:6296–6305
Bullinger L, Döhner K, Bair E, et al. (2004) Use of gene expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350:1605–1616
Valk PJ, Verhaak RG, Beijen MA, et al. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350:1617–1628
Marcucci G, Radmacher MD, Ruppet AS, et al. (2005) Independent validation of prognostic relevance of a previously reported gene-expression signature in acute myeloid leukemia with normal cytogenetics: A Cancer and Leukemia Group B Study. Blood 106:755 (abstr)
Wheatley K, Burnett AK, Goldstone AH, et al. (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties. Br J Haematol 107:69–79
Cassileth PA, Harrington DP, Appelbaum FR, et al. (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339:1649–1656
Zittoun RA, Mandelli F, Willemze R, et al. (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemocherapy in AML. N Engl J Med 332:217–223
Burnett AK, Wheatley K, Goldstone AH, et al. (2002) The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial. Br J Haematol 118:385–400
Jourdan E, Boiron J, Dastugue N, et al. (2005) Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: An intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol 23: 7676–7684
Gale R, Hills R, Kottaridis PD, et al. (2005) No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): An analysis of 1135 patients excluding promyelocytic leukemia from the UK MRC AML10 and 12 trials. Blood 106:3658–3665
Berman E, Little C, Gee T, et al. (1992) Reasons that patients with AML do not undergo allogeneic bone marrow transplantation. N Engl J Med 326:156–160
Proctor SJ, Taylor PRA, Stark A, et al. (1995) Evaluation of the impact of allogeneic transplant in first remission on an unselected population of patients with AML aged 15–55 years. Leukemia 9:1246–1251
Burnett AK, Goldstone AH, Stevens RM, et al. (1998) Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial. UK Medical Research Council Adult and Children’s Leukaemia Working Parties. Lancet 351:700–708
Stone RM, Berg DT, George SL, et al. (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary AML. N Engl J Med 332:1671–1677
Godwin JE, Kopecky KJ, Head DR, et al. (1998) A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated AML: A Southwest Oncology Group Study 9031. Blood 91:3607–3615
Zittoun R, Suciu S, Mandelli F, et al. (1996) Granulocyte-macrophage colony-stimulating factor associated with induction treatment of AML: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 14:2150–2159
Lowenberg B, Boogaerts MA, Daenen SMGJ, et al. (1997) The value of different modalities of GM-CSF applied during or after induction therapy of AML. J Clin Oncol 15:3496–3506
Lowenberg B, Suciu S, Archimbaud E, et al. (1997) Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-21, a phase III randomised study of the EORTC-LCG and HOVON groups. Blood 90:2952–2961
Lowenberg B, van Putten W, Theobald M, et al. (2003) Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 349:743–752
Estey E, Smith T, Keating M, et al. (1989) Prediction of survival during induction therapy in patients with newly diagnosed AML. Leukemia 3:257–263
Thall P, Estey E (2001) Graphical methods for evaluating covariate effects in the Cox model. In: Crowley J (ed) Handbook of statistics in clinical oncology. Marcel Dekker, New York, pp 411–433
Weick J, Kopecky K, Appelbaum F, et al. (1996) A randomised investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study. Blood 88:2841–2851
Bradstock KF, Matthews JP, Lowenthal RM, et al. (2005) A randomised trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing highdose cytarabine. Blood 105:481–488
Byrd JC, Dodge RK, Carroll A, et al. (1999) Patients with t(8;21)(q22; q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17:3767–3775
Byrd JC, Ruppert AS, Mrózek K, et al. (2004) Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13; q22): Results from CALGB 8461. J Clin Oncol 22:1087–1094
Rowe JM, Neuberg D, Friedenberg W, et al. (2004) A phase 3 study and of priming with GM-CSF in older adults with AML: A trial by the Eastern Cooperative Oncology Group. Blood 103:479–485
Anderson JE, Kopecky KJ, Willman CL, et al. (2002) Outcome after induction chemotherapy for older patients with AML is not improved with mitoxantrone and etoposide compared to daunorubicin and cytarabine: A Southwest Oncology Group Study. Blood 100:3869–3876
Van der Holt B, Lowenberg B, Burnett AK, et al. (2005) The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated AML in relation to MDR1 status at diagnosis. Blood 106:2646–2654
Estey EH, Thall PF, Giles FG, et al. (2002) Gemtuzumab ozogamycin with or without interleukin 11 in patients 65 years of age or older with untreated AML or high-risk MDS: Comparison with idarubicin plus high-dose continuous infusion cytosine arabinoside. Blood 99:4343–4349
Kahn SB, Begg CB, Mazza JJ, Bennett JM, Bonner H, Glick JH (1984) Full dose vs. attenuated daunorubicin, cytosine arabinoside and 6-thioguanine in the treatment of acute non-lymphocytic leukemia in the elderly. J Clin Oncol 2:865–870
Amadori S, Suciu S, Stasi R, et al. (2005) Gemtuzumab ozogamycin as single-agent treatment for frail patients age 61 years of age and older with acute myeloid leukemia: Final results of AML-15B, a phase 2 study of the European Organization for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell’ Adulto Leukemia Groups. Leukemia 19: 1768–1773
National Comprehensive Cancer Network (NCCN) (2003) AML Panel. AML clinical practice guidelines. Journal of the NCCN, vol 1,4:520–539
Baer MR, George SL, Dodge RK, et al. (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100:1224–1232
Sekeres MA, Stone RM, Zahrieh D, et al. (2004) Decision-making and quality of life in older adults with AML or advanced MDS. Leukemia 18:809–816
Estey E, Pierce S, Keating M (2000) Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica 85:246–249
Bishop JF, Lowenthal RM, Joshua D, et al., for the Australian Leukemia Study Group (1990) Etoposide in acute nonlymphocytic leukemia. Blood 75:27–32
Bishop J, Matthews J, Young G, et al. (1996) A randomised trial of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710–1717
Estey E, Wang X-M, Thall P, et al. (2004) Plausibility of delaying induction therapy in untreated AML. Blood 104:879a (abstr)
Lowenberg B, Zittoun R, Kerkhofs H, et al. (1989) On the value of intensive remission induction therapy in elderly patients of 65 + years with AML: A randomized phase III study of the European Organization for Research and Treatment of Cancer Group. J Clin Oncol 7:1268–1274
Burnett AK, Milligan D, Prentice AG, et al. (2004) Low dose ara-C versus hydroxyurea with or without retinoid in older patients not considered fit for intensive chemotherapy: The UK NCRI AML14 trial. Blood 104:872a (abstr)
Tilly H, Castaigne S, Bordessoule D, et al. (1990) Low dose cytarabine vs. intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8:272–279
Lancet J, Gotlib J, Gojo I, et al. (2004) Tipifarnib (ZARNESTRATM) in previously untreated poor-risk AML of the elderly: Updated results of a multicenter phase 2 trial. Blood 104:874a (abstr)
Stone R, DeAngelo D, Klimek V, et al. (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105:54–60
Smith D, Levis M, Beran M, et al. (2004) Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103:3669–3676
Knapper S, Burnett A, Kell J, et al. (2004) A phase II trial of the FLT3 inhibitor CEP701 as first line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 104:864a (abstr)
Attar E, DeAngelo D, Ballen K, et al. (2004) Phase I dose escalating trial of bortezomib (in combination with idarubicin and cytarabine in patients with acute myeloid leukemia. Blood 104: 1799a (abstr)
Kantarjian H, Ravandi F, O’Brien S, et al. (2004) Decitabine lowdose schedule (100 mg/m2/course) in myelodysplastic syndrome. Comparison of 3 different dose schedules. Blood 104: 1437a (abstr)
Lubbert M, Ruter B, Schmid M, et al. (2005) Continued low-dose decitabine is an active first-line treatment of older AML patients: First results of a multicenter phase II study. Blood 106:527a (abstr)
Burnett A, Russell N, Kell J, Milligan D, Culligan D (2004) A phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. Blood 104:869a (abstr)
Giles F, Thomas D, Garcia-Manero G, et al. (2004) A phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 10:2908–2917
Marcucci G, Stock W, Dai G, et al. (2005) Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 23:3404–3411
Gerrard G, Payne E, Baker RJ, et al. (2004) Clinical effects and Pglycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 89:782–790
Kell W, Burnett A, Chopra R, et al. (2003) A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102: 4277–4283
De Angelo D, Stone RM, Durant S, et al. (2003) Gemtuzumab ozogamicin (Mylotarg) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: Two age-specific phase 2 trials. Blood 102:100a (abstr)
Kolitz J, George S, Dodge R, et al. (2004) Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of cancer and leukemia group B study 9621. J Clin Oncol 22:4290–4301
Kolb HJ, Schattenberg A, Goldman JM, et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia Blood 86:2041–2050
Molldrem JJ (2006) Vaccination for leukemia. Biol Blood Marrow Transplant 12:13–18
Qazilbash M, Wieder E, Rios R, et al. (2004) Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood 104:259 (abstr)
Azuma T, Makita M, Ninomiya K, et al. (2002) Identification of a novel WT-1-derived peptide which induces human leukocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Brit J Haematol 116:601–603
Keilholz U, Scheibenbogen C, Letsch A, et al. (2005) WT1-peptide vaccination shows high immunogenicity and clinical activity in patients with acute myeloid leukemia. Blood 106:122a (abstr)
Tibes R, de Lima M, Estey E, Shahjahan R, Champlin R (2005) Nonmyeloablative HSCT in elderly AML/MDS patients in first CR. Proc Am Soc Clin Oncol ASCO abstract # 6655
Pagel J, Appelbaum F, Eary J (2006) 1311-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107:2184–2191
Sievers EL, Larson RA, Stadtmauer EA, et al. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive AML in first relapse. J Clin Oncol 19:3244–3254
Estey E, Garcia-Manero G, Giles F, Cortes J, O’Brien S, Kantarajian H (2005) Clinical relevance of CRp in untreated AML. Blood 106 (abstr)
Estey E (2000) Treatment of relapsed and refractory acute myeloid leukemia. Leukemia 14:476–479
Breems D, Van Putten W, Huijgens P, et al. (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23:1969–1978
Wong R, Shajahan M, Wang X, et al. (2005) Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11:108–114
Gorello P, Cazzaniga G, Alberti F, et al. (2006) Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia Mar 16 [Epub ahead of print]
Vidriales M, San Miguel J, Orfao A, et al. (2003) Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol 16(4):599–612
Kern W, Voskova D, Schoch C, et al. (2004) Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104:3078–3085
San Miguel J, Vidriales M, Lopez-Berges C, et al. (2001) Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98:1746–1751
Estey E (2004) Clinical trials in AML of the elderly: Should we change our methodology? Leukemia 18:1772–1774
Estey E, Thall P (2003) New designs for phase 2 clinical trials. Blood 102:442–448
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Estey, E. (2008). Therapy of AML. In: Acute Leukemias. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72304-2_1
Download citation
DOI: https://doi.org/10.1007/978-3-540-72304-2_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-72302-8
Online ISBN: 978-3-540-72304-2
eBook Packages: MedicineMedicine (R0)